Bispecific Antibodies to PD-1 and CTLA4: Doubling Down on T Cells to Decouple Efficacy from Toxicity

Abstract Summary: Although combination anti–PD-1 and anti-CTLA4 mAbs have revolutionized outcomes for many cancers, their utility has been limited due to significant immune-related toxicities the emergence of resistance. In this issue Cancer Discovery, Dovedi colleagues describe development preclinical testing MEDI5752, a bispecific anti–PD-1/CTLA4 antibody designed optimize therapeutic response by maximizing CTLA4 blockade on antigen-experienced T cells, thereby increasing efficacy potentially minimizing toxicity. See related article et al., p. 1100.